Fingerprint
Dive into the research topics of 'Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically